Organicell Regenerative Medicine Inc logo

Organicell Regenerative Medicine Inc

$ 0.03 +0.0041 (+14.86%) 10:08 PM EST
P/E:
At Loss
P/B:
0
Market Cap:
$ 46.79M
Enterprise V:
$ 47.98M
Volume:
772.36K
Avg Vol (2M):
1.13M
Volume:
772.36K
Market Cap $:
46.79M
PE Ratio:
At Loss
Avg Vol (2-Month):
1.13M
Enterprise Value $:
47.98M
PB Ratio:
0
GF Score:
Year:
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website SEC Filings Stock Report
Dataset
Financial Download

Business Description

Description
Organicell Regenerative Medicine Inc is a clinical-stage biopharmaceutical company principally focusing on the development of innovative biological therapeutics for the treatment of degenerative diseases. Its product candidate, Zofin is an acellular, biologic therapeutic that is naturally derived and manufactured to retain naturally occurring microRNAs without the addition or combination of any other substance. Zofin is in Phase I/II clinical trials to treat Long COVID and COPD. The company has entered an agreement with CDC to determine the anti-inflammatory and anti-infective effectiveness of Zofin in experimental models of influenza infection.

Financial Strength

Name Current Vs Industry Vs History
Cash-To-Debt 0.06
Equity-to-Asset -1.8
Debt-to-Equity -0.27
Debt-to-EBITDA -0.2
Piotroski F-Score 5/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -30.88
Distress
Grey
Safe
Beneish M-Score -12.07
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Growth Rank

Name Current Vs Industry Vs History
3-Year Revenue Growth Rate 7.7
3-Year FCF Growth Rate -14.5
3-Year Book Growth Rate 12.6

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI 45.96
9-Day RSI 47.52
14-Day RSI 47.92
6-1 Month Momentum % 105.41
12-1 Month Momentum % -40.63

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 0.06
Quick Ratio 0.05
Cash Ratio 0.01
Days Inventory 109.56
Days Sales Outstanding 4.8
Days Payable 1360.57

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -37.4

Profitability Rank

Name Current Vs Industry Vs History
Gross Margin % 91.2
Operating Margin % -98.51
Net Margin % -101.82
ROA % -325.45
ROIC % -258.12
ROC (Joel Greenblatt) % -428.82

GF Value Rank

Name Current Vs Industry Vs History
PS Ratio 4.53
EV-to-EBIT -7.37
EV-to-EBITDA -7.47
EV-to-Revenue 7.15
EV-to-FCF -17.88
Earnings Yield (Greenblatt) % -13.57

Financials

OCEL's 30-Y Financials

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with OTCPK:OCEL

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
To

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

Valuation Box

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 6.713
EPS (TTM) ($) -0.006
Beta 4.99
Volatility % 161.75
14-Day RSI 47.92
14-Day ATR ($) 0.008011
20-Day SMA ($) 0.031748
12-1 Month Momentum % -40.63
52-Week Range ($) 0.01 - 0.065
Shares Outstanding (Mil) 1,476.13

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 5
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Organicell Regenerative Medicine Inc Filings

Document Form Filing Date
No Filing Data

Organicell Regenerative Medicine Inc Analysis

Share your research

Headlines

See More
No news.